[Cost-effectiveness of using rubidium-82 chloride perfusion PET for planning myocardial revascularization procedures]

The aim of this study is to evaluate the cost-effectiveness, diagnostic accuracy, clinical outcomes, and radiation exposure associated with rubidium-82 chloride perfusion PET.

A comprehensive literature search up to October 2024 was conducted to identify key studies assessing the use of rubidium-82 chloride perfusion PET/CT in ischemic heart disease (IHD). These studies included economic analyses, evaluations of diagnostic accuracy, and comparisons with other imaging modalities such as single-photon emission computed tomography (SPECT), stress echocardiography, and invasive coronary angiography.

The reviewed studies demonstrate that rubidium-82 chloride perfusion PET/CT has high sensitivity and specificity in detecting IHD (90% and 91%, respectively) accompanied by significant coronary artery stenosis. Economic analyses show that this method is cost-effective due to a reduction in the use of downstream invasive procedures, leading to overall cost savings. Additionally, the economic impact on healthcare is enhanced by a lower level of radiation exposure compared to traditional perfusion SPECT imaging, reducing associated future radiation risks. The cost-effectiveness and minimum patient throughput required for implementing this modality In Russia were evaluated.

The presented data confirm the cost-effectiveness of rubidium-82 chloride perfusion PET/CT by reducing costs for subsequent diagnostic and therapeutic interventions while maintaining a sufficient patient flow.